CN106822207A - The new application of globe artichoke stem-leaf extract - Google Patents
The new application of globe artichoke stem-leaf extract Download PDFInfo
- Publication number
- CN106822207A CN106822207A CN201710037083.5A CN201710037083A CN106822207A CN 106822207 A CN106822207 A CN 106822207A CN 201710037083 A CN201710037083 A CN 201710037083A CN 106822207 A CN106822207 A CN 106822207A
- Authority
- CN
- China
- Prior art keywords
- globe artichoke
- leaf extract
- artichoke stem
- liver
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses the new application of globe artichoke stem-leaf extract, globe artichoke stem-leaf extract has anti-inflammatory, preventing and treating chronic alcohol liver injury, an effect of preventing and treating NASH, those effects be by reduce TLR4, NF κ B, IL 1 β, IL 6, IL 8 expression quantity realize.Globe artichoke stem-leaf extract of the invention can play manifold effect, Mutiple Targets, multi-functional effect, and with existing oral Antialcoholic liver-protecting medicine phases ratio, security is higher；And preparing convenient, market application foreground is wide, can be applied to prepare medicine, health food and food additives, feed addictive and antioxidant etc., is had broad application prospects and huge economic benefit in processed and applied field.
Description
Technical field
The invention belongs to pharmaceutical technology field, and in particular to the new application of globe artichoke stem-leaf extract.
Background technology
With expanding economy and the raising of people's level of consumption, AML (Alcohol liver disease,
ALD) the common prevalence in the whole world is become with NASH (non-alcoholic liver disease, NAFLD)
Hepatopathy, constitutes world's morbidity and mortality one of the main reasons.ALD patient can develop into alcoholic hepatitis (alcoholic
Steatohepatitis, ASH), NAFLD patient can develop into nonalcoholic fatty liver disease (non-alcoholic
Steatohepatitis, NASH), and ASH and NASH can be further development of liver fibrosis, cirrhosis, finally develop into
Liver cancer, each stage is progressively progressive can also to be existed simultaneously.If appropriate control can be carried out in the early stage (such as ASH, NASH) of hepatopathy
System, can will effectively prevent the deterioration of the state of an illness.
Existing multinomial report confirms the pathogenesis of the Inflammatory Pathway in ALD and NAFLD of gut derived exndotoxin induction at present
In play a significant role.Endotoxin is the part of gram-negative bacterial cell wall, when gut barrier is impaired, endogenous toxic material
Plain (also known as lipopolysaccharides, lipopolysaccharide, LPS) just releasably enters liver with other bacterial products.LPS enters
Liver activates nuclear transcription factor-kappa B (nuclear after being combined with Toll-like receptor 4 (Toll-like receptor 4, TLR4)
Factor- κ B, NF- κ B), and then promote inflammatory factor such as interleukin-1 beta (interleukin-1recptor, IL-1 β),
The release of interleukin-6 (IL-6), interleukin 8 (IL-8) etc., so that sb.'s illness took a turn for the worse.
Still lack effective treatment method and specific medicament for the treatment of ALD and NAFLD both at home and abroad, it is clinically to use anti-oxidant class more
Medicine, fall lipid drug and hepatic drug combination, although part lipid lowering agent has short term efficacy to ALD and NAFLD,
Side effect is more, influences liver function, blood fat is focused more on liver metabolism system, and burden of liver is aggravated on the contrary, causes aggravation.
In view of lacking the specific medicament for the treatment of Chronic Alcohol liver and NASH, find new hepatosis treating medicine and have become
One of focus of new drug research in recent years.Herbal drug is even more due to showing lighter side effect and more over the course for the treatment of
Therapy target once causing the extensive concern of scholar.
Globe artichoke (Artichoke), alias cynara scolymus, arithoke, chrysanthemum Ji, lotus lily, French lily, scientific name Cynara
Scolymus L. are that composite family cynara scolymus belongs to herbaceos perennial.Globe artichoke as a kind of food materials of medicine-food two-purpose, with variation
Activity.But there is not its report being applied on inflammation, chronic alcohol liver injury and NASH so far.
The content of the invention
It is an object of the invention to overcome the deficiencies in the prior art part, there is provided the new use of globe artichoke stem-leaf extract
On the way.
One of the technical solution adopted for the present invention to solve the technical problems is：
Purposes of the globe artichoke stem-leaf extract on anti-inflammatory drug and/or health-care products are prepared.
The two of the technical solution adopted for the present invention to solve the technical problems are：
Use of the globe artichoke stem-leaf extract on the medicine and/or health-care products for preparing preventing and treating chronic alcohol liver injury
On the way.
The three of the technical solution adopted for the present invention to solve the technical problems are：
Purposes of the globe artichoke stem-leaf extract on the medicine and/or health-care products for preparing preventing and treating NASH.
In one embodiment：The purposes is realized by globe artichoke stem-leaf extract by reducing TLR4 expression quantity.
In one embodiment：The purposes is realized by globe artichoke stem-leaf extract by reducing NF- κ B expression quantity.
In one embodiment：The purposes is realized by globe artichoke stem-leaf extract by reducing IL-1 β expression quantity.
In one embodiment：The purposes is realized by globe artichoke stem-leaf extract by reducing IL-6 expression quantity.
In one embodiment：The purposes is realized by globe artichoke stem-leaf extract by reducing IL-8 expression quantity.
The four of the technical solution adopted for the present invention to solve the technical problems are：
The preparation method of above-mentioned globe artichoke stem-leaf extract, including：
1) globe artichoke cauline leaf is crushed the globe artichoke powder for being made 40~60 mesh；
2) globe artichoke powder is extracted 1~3 time with 2~4 times of 70~85% alcohol refluxs of amount, and 1~3h, is extracted every time
Liquid；
3) by step 2) extract solution that obtains is condensed into the medicinal extract of 20~25 Baume degrees, and concentration time is not more than 4.5h, dense
Temperature is not higher than 65 DEG C during contracting；
4) by step 3) spray drying of the medicinal extract that obtains is made dry powder；
5) by step 4) dry powder that obtains crushed 80 mesh sieves, obtained final product globe artichoke stem-leaf extract.
Compared with background technology, it has the following advantages that the technical program：
1st, globe artichoke stem-leaf extract of the invention and existing oral Antialcoholic liver-protecting medicine phases ratio, as a kind of medicine-food two-purpose
Food, security is higher.
2nd, globe artichoke stem-leaf extract of the invention can play manifold effect, Mutiple Targets, multi-functional effect.
3rd, globe artichoke stem-leaf extract of the invention is prepared conveniently, and market application foreground is wide, can be applied to medicine and health care
Food additives, feed addictive and antioxidant outside food etc., have more in processed and applied field and have broad application prospects
With huge economic benefit.
Brief description of the drawings
The invention will be further described with reference to the accompanying drawings and examples.
Fig. 1 a are globe artichoke stem-leaf extract to chronic alcohol liver injury rat liver TLR4 and NF- κ B immuning tissues
Influence result microphoto, Fig. 1 b and Fig. 1 c is respectively the accumulation optical density (IOD) of TLR4 and NF- κ B；Wherein, CG is for just
Normal control group, MG is model group, and PCG is positive controls, and LDG is globe artichoke low dose group (0.4g/kg), and MDG is globe artichoke
Middle dose group (0.8g/kg), HDG is globe artichoke high dose group (1.6g/kg).Note：Compared with Normal group,***p<0.001；
Compared with model group,#p<0.05,##p<0.01,###p<0.001。
Fig. 2 a are globe artichoke stem-leaf extract to rats with nonalcoholic fatty liver disease liver TLR4 and NF- κ B immunohistochemistries
Influence result microphoto, Fig. 2 b and Fig. 2 c is respectively the accumulation optical density (IOD) of TLR4 and NF- κ B；Wherein, CG is normal
Control group, MG is model group, and PCG is positive controls, and LDG is globe artichoke low dose group (0.4g/kg), and MDG is in globe artichoke
Dosage group (0.8g/kg), HDG is globe artichoke high dose group (1.6g/kg).Note：Compared with Normal group,**p<0.01；With mould
Type group is compared,#p<0.05,##p<0.01。
Fig. 3 is influence result of the globe artichoke stem-leaf extract to chronic alcohol liver injury rat liver tissue pathological change
Microphoto.Wherein, CG is Normal group, and MG is model group, and PCG is positive controls, and LDG is globe artichoke low dose group
(0.4g/kg), MDG is globe artichoke middle dose group (0.8g/kg), and HDG is globe artichoke high dose group (1.6g/kg).
Fig. 4 is that globe artichoke stem-leaf extract shows to the influence result of rats with nonalcoholic fatty liver disease liver organization pathological change
Micro- photo.Wherein, CG is Normal group, and MG is model group, and PCG is positive controls, and LDG is globe artichoke low dose group
(0.4g/kg), MDG is globe artichoke middle dose group (0.8g/kg), and HDG is globe artichoke high dose group (1.6g/kg).
Fig. 5 is globe artichoke stem-leaf extract production technological process.
Specific embodiment
Present disclosure is illustrated below by embodiment：
Embodiment
The preparation of globe artichoke stem-leaf extract：Globe artichoke cauline leaf is provided by Hui Mei agricultural developments Co., Ltd of Hunan Province；
(1) material pre-treatment：Clean → 60 DEG C of drying of globe artichoke cauline leaf → clear water → crush → cross 40~60 mesh sieves → court
Fresh Ji powder.
(2) extract：In 3T multi-function extractors put into 800kg globe artichoke powder, with 3 times amount (mass volume ratio) 75~
80% alcohol reflux extracts secondary, 2 hours every time.Extract solution is put into extraction liquid storage tank after filtering.
(3) concentrate：The medicinal extract of 20~25 Baume degrees (heat is surveyed) will be concentrated into extract solution suction outer circulation decompression concentrator.
The concentration process cumulative time, temperature was no more than 60 DEG C no more than 4 hours.
(4) dry：Medicinal extract is spray-dried to obtain dry powder.
(5) crush, mix, pack：Dry powder is crushed, 80 mesh sieves are crossed, globe artichoke stem-leaf extract is obtained final product, packed.
Experimental example
The present invention is illustrated below by rat chronic alcoholic liver injury model and Making Rat Models of Nonalcoholic
Globe artichoke stem-leaf extract played by regulating and controlling TLR4/NF- κ B signals paths anti-inflammatory, preventing and treating chronic alcohol liver injury and
The effect of NASH.
First, experiment material
1.1 experimental animals
Cleaning grade Sprague-Dawley rats 96, male, 8 week old, 220 ± 5g of body weight is tested by Shanghai Si Laike
Company of Animals Ltd. provides.The quality certification is numbered：20070000579702, ticket number：SCXK (Lu) 2012-2002.Rat
Before experiment, (all rats can contact free liquid for 22 ± 2 DEG C of temperature, relative humidity 60 ± 5%) to raise 7 days through adaptability
Feed and drinkable water.
1.2 experiment reagents and medicine
Lieber-DeCarli alcohol liquids feed (protein calories 18%, alcohol heat 36%, other carbohydrate
Heat 11%, fat heat 35%) and Lieber-DeCarli non-alcohol liquid feed (protein calories 18%, carbon hydrate
Thing heat 47%, fat heat 35%) it is purchased from Nantong Te Luofei feed technologies Co., Ltd；
High lipid food is purchased from Foochow Wu Shi experimental animals trade Co., Ltd (lard 12%, cholesterol 2%, propylthio oxygen
Pyrimidine 0.2%, sodium taurocholate 0.5%, normal diet powder 85.5%)；
DDB is purchased from Beijing XieHe medicine Factory；
Fenofibrate is purchased from Guangdong first strong medicine company；
ALT, AST, TG, TC measure kit are purchased from Nanjing and build up Bioengineering Research Institute；
IL-1 β, IL-6, IL-8 determine kit and are purchased from the enzyme-linked Bioisystech Co., Ltd in Shanghai；
TLR4 antibody is purchased from Novus Biologicals companies of the U.S.；
NF- kappa B antibodies are purchased from Origene companies of the U.S..
2nd, experimental technique
2.1 experimental animals are grouped and administration
96 rats are bisected into two big groups at random, and every group 48, one group of feeding alcohol liquid feed builds alcoholic liver and damages
Wound model, one group of feeding high lipid food builds nonalcoholic fatty liver model.
2.1.1 alcoholic liver injury model
Experimental rat is randomly divided into 6 groups, every group 8, sub-cage rearing.Animal is divided into：Normal group, model comparison
Group, positive control (DDB) group, basic, normal, high group of globe artichoke.Control group rat gives the non-alcohol liquids of Lieber-DeCarli
Body feedstuff, and remaining five groups of experimental group gives Lieber-DeCarli alcohol liquid feeds.Globe artichoke each group (basic, normal, high component
Not Wei 0.4,0.8,1.6g/kg/d) and positive controls (0.36g/kg/d) with the preparation gavage of corresponding dosage, blank group gavage
Isometric physiological saline.It is continuous to feed 8 weeks.
2.1.2 nonalcoholic fatty liver model
Experimental rat is randomly divided into 6 groups, every group 8, sub-cage rearing.Animal is divided into：Normal group, model comparison
Group, positive control (fenofibrate) group, basic, normal, high group of globe artichoke.Normal group with normal diet feeding, free water and
Feed, model group high lipid food nursing, free water and feed.Globe artichoke each group (basic, normal, high group be respectively 0.4,0.8,
1.6g/kg/d) with positive controls (0.36g/kg/d) with the preparation gavage of corresponding dosage, the isometric physiology salt of blank group gavage
Water.It is continuous to feed 8 weeks.
2.2 materials
In 16 weekend each group Rat Fast 12 hours, rat body weight is weighed before putting to death.Extract eyeball and take blood, fix rat,
Cut open the belly, be rapidly separated taking-up liver, in 0.9% normal saline flushing, claim wet liver weight, calculate liver index, observation liver morphology and
Surface color, takes out rapidly right lobe of liver tissue number fritter in -80 DEG C of refrigerators are stored in after liquid nitrogen flash freezer, in case LH is prepared and revived
H ＆ E (hematoxylin and eosin, H＆E) dyeing observation hepatic tissue pathology situation.
Take one piece of hepatic tissue at right lobe of liver isolated edge 1cm to be fixed in 10% neutral formalin solution, 24 hours laggard
Row dehydration, with treating that immunohistochemical observation is used after FFPE.
After blood preparation stands 2 hours in 4 DEG C, 8000rpm is centrifuged 10 minutes, takes upper serum, and packing is stored in -80 DEG C
Refrigerator, in case liver biochemical indicator is detected.
The preparation of 10% liver tissue homogenate：Tissue samples are taken, clip tissue about 100mg weighs；Floated with 1mL physiological saline
Wash tissue 2 times；Blood is removed, filter paper is wiped dry, weighed, is put into 5mL beakers；With pipette volume ratio (g by weight:ML) add
Physiological saline, with pipettor take total amount 2/3 physiological saline in beaker, shred tissue block；The tissue that will be shredded pours into glass
In glass homogenate tube, then remaining normal saline flushing is remained in the hepatic tissue fragment in beaker, glass homogenate tube is poured into together
In be homogenized (carried out in ice bath)；By homogenate in being centrifuged 10 minutes under 3500rpm, supernatant is taken, obtain final product 10% hepatic tissue
Homogenate, standby liver Indexs measure.
2.3 liver index are determined
Liver index=[liver mass (g)/mouse quality (g)] × 100%.
2.4 Biochemical Indexes
Gained serum is operated in strict accordance with ALT, AST, TC, TG test kit operational procedure after centrifugation, is surveyed respectively
Fixed each biochemical marker level.
2.5 liver activity index and inflammatory factor are determined
10% LH of gained is grasped in strict accordance with IL-1 β, IL-6 and IL-8 test kit operational procedures after centrifugation
Make, each biochemical marker level is determined respectively.
2.6 hepatic tissue pathologies are detected
Hepatic tissue sample is fixed with 10% neutral formalin solution, conventional dehydration, specimens paraffin embedding slices, Chang GuiH ＆E dyeing, light
(× 200) observation hepatic tissue pathology changes under learning microscope.
The expression of TLR4 and NF- κ B in 2.7 immunohistochemical methods detection hepatic tissue
Hepatic tissue FFPE, section, conventional dewaxing, after graded ethanol dehydration, be put into for section by Microwave method antigen
In 3% hydrogen peroxide of the fresh configuration of methyl alcohol, 10 minutes are stood, close endogenous peroxydase, lowlenthal serum closing is non-specific
Property antigen, rabbit-anti rat TLR4 polyclonal antibodies (1 are added dropwise respectively：50), rabbit-anti rat NF- κ B polyclonal antibodies (1：250), 4
DEG C overnight incubation, PBS is washed (phosphate buffer saline, PBS) 3 and is washed, each 10mL, and polymerization is added dropwise
Thing reinforcing agent and horseradish enzyme mark goat antirabbit/mouse IgG polymer, diaminobenzidine DAB color development at room temperature, haematoxylin are multiple
Dye, dehydration, transparent, mounting.Feminine gender just replaces primary antibody frequently with PBS.(× 200) randomly choose 5 not under an optical microscope
Repeat the visual field, endochylema or karyon are sepia or brown color is positive cell.It is soft using Image-ProPlus6.0 graphical analyses
The accumulative OD value of part detection.
2.8 statistical methods
All detections carry out three parallel laboratory tests, p<0.05 thinks with statistical significance.Data are united using SPSS18.0
Meter learns software processing.Result with average value ± standard deviation (mean plus/minus standard deviation, mean ±
SD) represent, group difference uses one-way analysis of variance.
3rd, interpretation of result
3.1 pairs of influences of rats'liver weight, body weight and liver index
3.1.1 to the influence of chronic alcohol liver injury rats'liver weight, body weight and liver index
The body weight of model group rats and liver weight are significantly reduced compared with rats in normal control group, the significantly raised (p of liver index<
0.05).The basic, normal, high dosage group for giving globe artichoke can in various degree reduce elevated liver index, and difference has statistical significance
(p<0.05).As shown by data, the liver fat that globe artichoke stem-leaf extract is caused to alcohol is piled up has certain mitigation to act on.It is real
Test data as shown in table 1.
Influence (mean of the globe artichoke stem-leaf extract of table 1 to chronic alcohol liver injury rats'liver weight, body weight and liver index
± SD, n=8)
Note：Compared with Normal group,*p<0.05；Compared with model group,#p<0.05。
3.1.2 to the influence of rats with nonalcoholic fatty liver disease liver weight, body weight and liver index
The liver weight of model group rats has substantially reduction compared with rats in normal control group, and body weight also substantially increases, additionally, liver index
Significantly raise, difference has statistical significance (p<0.01).The basic, normal, high dosage group for giving globe artichoke is reduced in various degree
Liver index, and can substantially observe that liver index is negatively correlated with the use of globe artichoke dosage.Experimental data is as shown in table 2.
The globe artichoke stem-leaf extract of table 2 to non-alcoholic fatty rats'liver weight, body weight and liver index influence (mean ±
SD, n=8)
Note：Compared with Normal group,**p<0.01；Compared with model group,#p<0.05。
The influence of ALT, AST, TG, TC level in 3.2 pairs of rat blood serums
3.2.1 to the influence of ALT, AST, TG and TC level in chronic alcohol liver injury rat blood serum
ALT, AST, TG and TC of model group rats are significantly raised compared with rats in normal control group, have been respectively increased 244.73%
(p<0.001), 157.25% (p<0.001), 110.73% (p<0.01) with 235.31% (p<0.001) alcohol, is as a result shown
Property liver injury model is successfully established.Globe artichoke treatment group reduces elevated Serum Indexes, and globe artichoke high dose group is significantly reduced
Elevated ALT, AST, TG and TC, can be clearly visible ALT, AST and TG content and globe artichoke in ALT, AST and TG changes of contents
Dosage is negatively correlated.Experimental data is as shown in table 3.
The globe artichoke stem-leaf extract of table 3 to chronic alcohol liver injury rat blood serum ALT, AST level influence (mean ±
SD, n=8)
Note：Compared with Normal group,**p<0.01,***p<0.001；Compared with model group,#p<0.05,##p<0.01,###
p<0.001。
3.2.2 the influence of ALT, AST, TG and TC level in rat blood serum is damaged to NASH
ALT, AST, TG, TC of model group rats significantly raise (p compared with rats in normal control group<0.001), it is respectively increased
118.32%, 342.27%, 136.29%, 223.46%.Globe artichoke treatment group can significantly reduce elevated Serum Indexes, by
ALT understands that globe artichoke middle dose group therapeutic effect is suitable with fenofibrate with AST changes of contents, and contains quantitative change in TG, TC and FFA
In change, globe artichoke high dose group therapeutic effect is better than fenofibrate group.In addition, TG can be clearly visible in TG and TC changes of contents
Negatively correlated with globe artichoke dosage with TC contents, experimental data is as shown in table 4.
The globe artichoke stem-leaf extract of table 4 to rats with nonalcoholic fatty liver disease Serum ALT, AST levels influence (mean ±
SD, n=8)
Note：Compared with Normal group,***p<0.001；Compared with model group,#p<0.05,##p<0.01,###p<0.001。
3.3 pairs of influences of liver tissues of rats TLR4 and NF- κ B expression
TLR4 expression is located at cytoplasm and cell membrane, and positive cell is sepia or yellow.NF- κ B are mainly expressed in cell
Core, positive cell is sepia.
3.3.1 to the influence of chronic alcohol liver injury liver tissues of rats TLR4 and NF- κ B expression
The expression of TLR4 and NF- κ B is obviously improved compared with Normal group in Showed by immune group result model group, puts down
Equal OD value result shows that TLR4 and the expression quantity of NF- κ B improve 93.00% and 80.81% respectively.Three of globe artichoke
Dosage group significantly inhibits its expression, and can substantially observe, globe artichoke stem-leaf extract to the expression inhibiting effect of NF-kB and
Globe artichoke consumption is proportionate.Experimental result is as shown in Figure 1.
3.3.2 to the influence of rats with nonalcoholic fatty liver disease hepatic tissue TLR4 and NF- κ B expression
The expression of TLR4 and NF- κ B is obviously improved compared with Normal group in Showed by immune group result model group, puts down
Equal OD value result shows that TLR4 and the expression quantity of NF- κ B improve 19.36% and 23.39% respectively.Three of globe artichoke
Dosage group significantly reduces its expression quantity, and can substantially observe, expression of the globe artichoke stem-leaf extract to TLR4 and NF- κ B presses down
Effect processed is proportionate with globe artichoke consumption.Experimental result is as shown in Figure 2.
The influence of inflammatory factor IL-1 β, IL-6 and IL-8 levels in 3.4 pairs of rats with nonalcoholic fatty liver disease LHs
3.4.1 to the influence of inflammatory factor IL-1 β, IL-6 and IL-8 levels in chronic alcohol liver injury rat liver homogenate
Compared with Normal group, IL-1 β, IL-6 and IL-8 content of model group rats are significantly raised, and are respectively increased
77.21% (p<0.001), 89.76% (p<0.001) with 83.51% (p<0.001).Three dosage groups of globe artichoke
Significantly reduce its elevated content.Additionally, the therapeutic effect of globe artichoke is superior to the therapeutic effect of positive drug.Globe artichoke is three
The therapeutic effect of individual various dose group is better than positive treatment medicine.Experimental data as shown in table 5
The globe artichoke stem-leaf extract of table 5 is to IL-1 β, IL-6 and IL-8 levels in chronic alcohol liver injury rat liver homogenate
Influence (mean ± SD, n=8)
Note：Compared with Normal group,***p<0.001；Compared with model group,##p<0.01,###p<0.001。
3.4.2 to the influence of inflammatory factor IL-1 β, IL-6 and IL-8 levels in rats with nonalcoholic fatty liver disease LH
Compared with Normal group, IL-1 β, IL-6 and IL-8 content of model group rats are significantly raised, and are respectively increased
60.10% (p<0.01), 74.44% (p<0.001) with 78.54% (p<0.001).Three dosage groups of globe artichoke can show
Writing reduces its elevated content.Globe artichoke therapeutic effect is suitable with positive treatment medicine, and according to IL-6 changes of contents observables
It is negatively correlated with globe artichoke dosage to IL-6 contents.Experimental data is as shown in table 6.
The globe artichoke stem-leaf extract of table 6 is to IL-1 β, IL-6 and IL-8 levels in rats with nonalcoholic fatty liver disease LH
Influence (mean ± SD, n=8)
Note：Compared with Normal group,**p<0.01,***p<0.001；Compared with model group,##p<0.01,###p<
0.001。
3.5 pairs of rat liver tissue pathological examinations
Army can be observed in chronic alcohol liver injury rat and rats with nonalcoholic fatty liver disease：Normal group is big
Mouse has complete lobuli hepatis structure, and liver kytoplasm is preserved completely and liver cell nuclear is high-visible, without substantially downright bad, steatosis,
Without inflammatory cell infiltration and proliferation of fibrous tissue.However, in the model group rats liver slice after H＆E is dyeed, can be observed bright
Aobvious hepatic tissue pathology change, including the liver cell oedema of large area, necrosis and lobuli hepatis inflammatory reaction.Globe artichoke treatment group
In can be observed the regeneration of liver cell and the mitigation of inflammatory reaction, and serious vacuolar degeneration of hepatic cell is not observed and liver is thin
Born of the same parents' necrosis, shows that globe artichoke stem-leaf extract can protect liver from chronic alcohol liver injury and NASH
Infringement.Experimental result is as shown in Figure 3,4.
The above, only present pre-ferred embodiments, therefore can not according to this limit the scope of present invention implementation, i.e., according to
Equivalence changes that the scope of the claims of the present invention and description are made and modification, all should still belong in the range of the present invention covers.
Claims (9)
1. purposes of the globe artichoke stem-leaf extract on anti-inflammatory drug and/or health-care products are prepared.
2. globe artichoke stem-leaf extract prepare preventing and treating chronic alcohol liver injury medicine and/or health-care products on purposes.
3. globe artichoke stem-leaf extract prepare preventing and treating NASH medicine and/or health-care products on purposes.
4. the purposes according to claim 1 or 2 or 3, it is characterised in that：The purposes is passed through by globe artichoke stem-leaf extract
TLR4 expression quantity is reduced to realize.
5. the purposes according to claim 1 or 2 or 3, it is characterised in that：The purposes is passed through by globe artichoke stem-leaf extract
NF- κ B expression quantity is reduced to realize.
6. the purposes according to claim 1 or 2 or 3, it is characterised in that：The purposes is passed through by globe artichoke stem-leaf extract
IL-1 β expression quantity is reduced to realize.
7. the purposes according to claim 1 or 2 or 3, it is characterised in that：The purposes is passed through by globe artichoke stem-leaf extract
IL-6 expression quantity is reduced to realize.
8. the purposes according to claim 1 or 2 or 3, it is characterised in that：The purposes is passed through by globe artichoke stem-leaf extract
IL-8 expression quantity is reduced to realize.
9. the preparation method of the globe artichoke stem-leaf extract described in a kind of claim 1 or 2 or 3, it is characterised in that：Including：
1) globe artichoke cauline leaf is crushed the globe artichoke powder for being made 40~60 mesh；
2) globe artichoke powder is extracted 1~3 time with 2~4 times of 70~85% alcohol refluxs of amount, and 1~3h, obtains extract solution every time；
3) by step 2) extract solution that obtains is condensed into the medicinal extract of 20~25 Baume degrees, and concentration time is not more than 4.5h, during concentration
Temperature is not higher than 65 DEG C；
4) by step 3) spray drying of the medicinal extract that obtains is made dry powder；
5) by step 4) dry powder that obtains crushes, and obtains final product globe artichoke stem-leaf extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710037083.5A CN106822207A (en) | 2017-01-18 | 2017-01-18 | The new application of globe artichoke stem-leaf extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710037083.5A CN106822207A (en) | 2017-01-18 | 2017-01-18 | The new application of globe artichoke stem-leaf extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106822207A true CN106822207A (en) | 2017-06-13 |
Family
ID=59123271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710037083.5A Pending CN106822207A (en) | 2017-01-18 | 2017-01-18 | The new application of globe artichoke stem-leaf extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106822207A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107927779A (en) * | 2017-11-27 | 2018-04-20 | 爱可道生物科技有限公司 | A kind of beautifying face and moistering lotion oral liquid and preparation method thereof |
| CN110507786A (en) * | 2019-08-16 | 2019-11-29 | 爱可道生物科技有限公司 | A kind of arithoke compound product with protect liver, preparation method and application |
| CN114042095A (en) * | 2021-12-01 | 2022-02-15 | 爱可道生物科技有限公司 | Application of globe artichoke and its extract in preparing medicine for preventing hepatic injury caused by antituberculosis drugs |
| CN116999474A (en) * | 2023-06-27 | 2023-11-07 | 浙江省农业科学院 | Application of cynara scolymus extract |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104256809A (en) * | 2014-09-02 | 2015-01-07 | 汇美农业科技有限公司 | Method for preparing beverage by using globe artichoke stem and leaf extracts |
| CN105012259A (en) * | 2015-08-06 | 2015-11-04 | 华侨大学 | Artichoke extract dispersible tablets and preparing method thereof |
-
2017
- 2017-01-18 CN CN201710037083.5A patent/CN106822207A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104256809A (en) * | 2014-09-02 | 2015-01-07 | 汇美农业科技有限公司 | Method for preparing beverage by using globe artichoke stem and leaf extracts |
| CN105012259A (en) * | 2015-08-06 | 2015-11-04 | 华侨大学 | Artichoke extract dispersible tablets and preparing method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 曹佩琴等: "朝鲜蓟叶水提取物对酒精诱导人肝癌细胞株HepG2损伤的影响", 《食品安全质量检测学报》 * |
| 焦万田: "《新编简明药物手册》", 31 December 1993 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107927779A (en) * | 2017-11-27 | 2018-04-20 | 爱可道生物科技有限公司 | A kind of beautifying face and moistering lotion oral liquid and preparation method thereof |
| CN110507786A (en) * | 2019-08-16 | 2019-11-29 | 爱可道生物科技有限公司 | A kind of arithoke compound product with protect liver, preparation method and application |
| CN114042095A (en) * | 2021-12-01 | 2022-02-15 | 爱可道生物科技有限公司 | Application of globe artichoke and its extract in preparing medicine for preventing hepatic injury caused by antituberculosis drugs |
| CN116999474A (en) * | 2023-06-27 | 2023-11-07 | 浙江省农业科学院 | Application of cynara scolymus extract |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106822207A (en) | The new application of globe artichoke stem-leaf extract | |
| Li et al. | Effects of Lipid Regulation Using Raw and Processed Radix Polygoni Multiflori in Rats Fed a High‐Fat Diet | |
| Soumya et al. | A novel method of extraction of bamboo seed oil (Bambusa bambos Druce) and its promising effect on metabolic symptoms of experimentally induced polycystic ovarian disease | |
| CN114366804A (en) | Application of pea albumin in preparation of composition for relieving inflammatory bowel disease | |
| CN105106184A (en) | Application of astaxanthin in preparation of medicine curing decreased insulin sensitivity | |
| CN104940599A (en) | Application of traditional Chinese medicine composition in preparation of medicines for improving lipid metabolism | |
| CN105560265B (en) | Purposes of the Bupleurum chinense polysaccharide in the drug for preparing prevention diabetic nephropathy | |
| CN100408061C (en) | Medicine for treating cholestasis and hepatic fibrosis and method for preparing the same | |
| CN116768963A (en) | Dendrobium officinale protein preparation method, structural characterization and application thereof in gastric mucosa protection | |
| CN101204573B (en) | Medicine foe diabetes mellitus | |
| Shen et al. | Antidiarrheal effects of a thermostable protein fraction obtained from the larvae of Musca domestica | |
| CN108079217A (en) | One kind is made light of one's life by commiting suicide ball | |
| CN101167776B (en) | Chicory seed effective part and preparation method and application thereof | |
| CN112493483A (en) | Use of chlorophyll-rich spinach extract for relieving intestinal inflammatory response and barrier dysfunction | |
| CN103623150B (en) | Novel processing technology for lowering alisma nephrotoxicity | |
| CN101524386B (en) | Chinese herbal main component prescription for curing fatty liver | |
| CN101537086B (en) | Pharmaceutical composition for resisting hepatitis B virus, lowering lipid and alleviating fatty live lesions and preparation method thereof | |
| CN105726568B (en) | A kind of construction method of diabetic nephropathy animal model | |
| CN104688800B (en) | Application of the total saponins from Cornus officinalis in the drug of preparation prevention and treatment diabetic complication | |
| Li et al. | Protective effect of victory onion (Allium victorialis L.) extract on reproductive system injury in male rats | |
| Monteiro et al. | Liver morphology and morphometry and plasma biochemical parameters of Wistar rats that received leaf infusion of Rudgea viburnoides Benth.(Rubiaceae) | |
| CN103948780B (en) | A kind of medicine and capsule for constipation | |
| CN118217320A (en) | Application of Dingyinniong composition in preparation of medicines for preventing and/or treating non-alcoholic fatty liver disease | |
| CN118662574A (en) | Fermented traditional Chinese medicine composition and preparation method and application thereof | |
| CN116898845A (en) | Application of indobufen in preparation of non-alcoholic fatty liver disease drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170613 |
|
| RJ01 | Rejection of invention patent application after publication |